Business Wire

Shape Therapeutics to Highlight RNA Editing Technology Platform Advancements in Parkinson’s Disease and the Identification of Novel CNS-targeting AAV Variants at the J.P ...

SEATTLE--(BUSINESS WIRE)--Shape Therapeutics Inc. (Shape TX), a next-generation RNA-targeting gene therapy company, announces today the upcoming company presentation at the J.P. Morgan 39 th Annual ...
Business Insider

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases

TOKYO and SEATTLE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Shape TX, the programmable medicine company using AI and RNA to end genetic diseases, today announce ...
manilatimes

Shape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene Therapy at the European Society of ...

Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson's ...
DutchNews.NL

VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

~ Agreement grants VectorY the exclusive right to evaluate and license Shape’s non-invasive, deep-brain penetrating AAV5-derived capsid for vectorized antibodies against three targets ~ ~ License will ...
Labroots

How LV and AAV Transfection Platforms will Shape the Future of Gene Therapy Manufacturing

Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show great promise for treatment of diseases from genetic disorders to cancer.
ksn.com

Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations at ...